Skip to content
  • Sunday, 26 July 2026
  • 2:56 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • FDA Issues Landmark Guidance to Enhance Pregnancy Safety Data for Medications
Pharmaceutical R&D

FDA Issues Landmark Guidance to Enhance Pregnancy Safety Data for Medications

Teuku Ryan May 12, 2026 0

The US Food and Drug Administration (FDA) has unveiled its comprehensive final guidance for industry on collecting crucial post-marketing safety…

Read More
Pharmaceutical R&D

FDA Issues Complete Response Letter to Replimune’s RP1 for Advanced Melanoma

Teuku Ryan Apr 14, 2026 0

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Replimune Group’s Biologics License Application…

Read More
Sai Life Sciences Plans to Recruit 700+ Professionals in FY27 as Indian CRDMO Demand AcceleratesInflammatory Remodeling of the Bone Marrow Niche: New Insights into the Early Drivers of Clonal Hematopoiesis and Myelodysplastic SyndromeAre AI Agents Your Next Security Nightmare?Sanofi’s Venglustat Receives Priority Review from US FDA for Type 3 Gaucher Disease
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ